HK1217650A1 - 用於治疗剧痛的组合物及方法 - Google Patents

用於治疗剧痛的组合物及方法 Download PDF

Info

Publication number
HK1217650A1
HK1217650A1 HK16105731.5A HK16105731A HK1217650A1 HK 1217650 A1 HK1217650 A1 HK 1217650A1 HK 16105731 A HK16105731 A HK 16105731A HK 1217650 A1 HK1217650 A1 HK 1217650A1
Authority
HK
Hong Kong
Prior art keywords
methods
compositions
severe pain
treating severe
pharmaceutical compositions
Prior art date
Application number
HK16105731.5A
Other languages
English (en)
Chinese (zh)
Inventor
John Brew
Robin Mark Bannister
Original Assignee
Infirst Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infirst Healthcare Limited filed Critical Infirst Healthcare Limited
Publication of HK1217650A1 publication Critical patent/HK1217650A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK16105731.5A 2013-01-14 2014-01-14 用於治疗剧痛的组合物及方法 HK1217650A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752356P 2013-01-14 2013-01-14
US201361752356P 2013-01-14
PCT/EP2014/050628 WO2014108569A1 (en) 2013-01-14 2014-01-14 Compositions and methods for treating severe pain

Publications (1)

Publication Number Publication Date
HK1217650A1 true HK1217650A1 (zh) 2017-01-20

Family

ID=50064547

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105731.5A HK1217650A1 (zh) 2013-01-14 2014-01-14 用於治疗剧痛的组合物及方法

Country Status (14)

Country Link
EP (1) EP2943183A1 (enExample)
JP (1) JP6474732B2 (enExample)
KR (1) KR20150129665A (enExample)
CN (1) CN104968330A (enExample)
AU (1) AU2014204739B2 (enExample)
BR (1) BR112015015864B1 (enExample)
CA (1) CA2897874A1 (enExample)
HK (1) HK1217650A1 (enExample)
IL (1) IL239921A0 (enExample)
MX (1) MX2015009045A (enExample)
RU (1) RU2677346C2 (enExample)
SG (1) SG11201505245XA (enExample)
WO (1) WO2014108569A1 (enExample)
ZA (1) ZA201505005B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11896037B2 (en) * 2016-08-03 2024-02-13 Temple University-Of The Commonwealth System Of Higher Education Microencapsulation of active agents
JP7027786B2 (ja) * 2017-10-12 2022-03-02 ライオン株式会社 筋・筋膜性疼痛用の内服治療剤
WO2022207580A2 (en) 2021-03-27 2022-10-06 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics
CN116660550B (zh) * 2023-06-19 2024-08-13 南通大学 一种dgat2的抑制剂pf-06424439用于缓解疼痛的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
DK0989851T3 (da) * 1997-07-29 2003-01-27 Upjohn Co Selvemulgerende formulering indeholdende sure lipofile forbindelser
PT999826E (pt) * 1997-07-29 2004-09-30 Upjohn Co Formulacao auto-emulsionante para compostos lipofilos
GB2331458B (en) * 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
BR0010354A (pt) * 1999-05-07 2002-03-05 Pharmasol Gmbh Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção
US8663692B1 (en) * 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
DK1183014T3 (da) * 1999-06-14 2004-02-09 Cosmo Spa Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
JP3763567B2 (ja) * 2001-01-19 2006-04-05 株式会社資生堂 化粧料
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
EP1817012A2 (en) * 2004-11-24 2007-08-15 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
WO2006115463A1 (en) * 2005-04-28 2006-11-02 Galenica Technology Ab Pharmaceutical dosage forms comprising a lipid phase
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2009153496A2 (fr) 2008-05-26 2009-12-23 Genfit Composés agonistes ppar, préparation et utilisations
CN102048680B (zh) * 2009-11-11 2013-05-01 河北奥星集团药业有限公司 一种含有扎托布洛芬的肠溶缓释制剂及其制备方法
WO2012104655A2 (en) * 2011-02-04 2012-08-09 Biocopea Limited Compostions and methods for treating chronic inflammation and inflammatory diseases
CN102579350B (zh) * 2012-03-02 2013-04-24 海南灵康制药有限公司 右旋布洛芬脂质体固体制剂

Also Published As

Publication number Publication date
CN104968330A (zh) 2015-10-07
SG11201505245XA (en) 2015-08-28
RU2677346C2 (ru) 2019-01-16
KR20150129665A (ko) 2015-11-20
WO2014108569A1 (en) 2014-07-17
BR112015015864A8 (pt) 2018-01-16
EP2943183A1 (en) 2015-11-18
BR112015015864A2 (pt) 2017-07-11
IL239921A0 (en) 2015-08-31
CA2897874A1 (en) 2014-07-17
AU2014204739A1 (en) 2015-07-16
JP6474732B2 (ja) 2019-02-27
RU2015134136A (ru) 2017-02-20
AU2014204739B2 (en) 2016-08-11
JP2016504401A (ja) 2016-02-12
MX2015009045A (es) 2015-12-17
BR112015015864B1 (pt) 2022-08-23
ZA201505005B (en) 2016-10-26

Similar Documents

Publication Publication Date Title
HK1218621A1 (zh) 用於治疗慢性炎症和炎性疾病的组合物及方法
HK1217650A1 (zh) 用於治疗剧痛的组合物及方法
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
EP3052476A4 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
WO2015077503A8 (en) Autotaxin inhibitor compounds
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
EP3035992A4 (en) Compositions, methods and systems for the treatment of cutaneous disorders
EP3054932A4 (en) Dexmedetomidine transdermal delivery devices and methods for using the same
EP3250578A4 (en) Oligosaccharide compositions for use in nutritional compositions, and methods of producing thereof
EP3166648A4 (en) Compositions and delivery methods for treating dental infections, inflammation, sensitivity, and for use in dental restorations
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP3098224A4 (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
EP3048103A4 (en) Immune adjustment compound, use thereof and pharmaceutical composition comprising same
WO2014121137A3 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
EP3071214A4 (en) Salacia compositions, methods of treatment by their administration, and methods of their preparation
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
LT3087989T (lt) Kietos kompozicijos, apimančios tofoglifloziną, ir jų gamybos būdas
WO2014146111A3 (en) Analgesic compounds and methods of use
WO2017079403A3 (en) Polymeric nanoparticles
EP3040337A4 (en) 2, 6-di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof
HK1223300A1 (zh) 皮质类固醇组合物
EP3080246A4 (en) Compositions and methods for producing and administering brown adipocytes